J&J Teams with Foundation Medicine on Cancer Marker Studies

Oct 25, 2011

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it will partner with Johnson & Johnson Pharmaceutical Research and Development in a biomarker identification collaboration.

Under the agreement, the partners will use Foundation Medicine's clinical cancer genomic test to identify biomarkers that will support J&JPRD's clinical development programs.

The Cambridge, Mass.-based company's cancer diagnostic test uses next-generation sequencing to analyze specimens for variations in over 200 cancer-related genes, and it is optimized for analysis of tissue complexities that are inherent in tumor genomes.

"Our test may help identify patients that are more likely to respond to targeted therapies, which could accelerate clinical development and give physicians additional ways to effectively treat patients," Foundation Medicine President and CEO Michael Pellini explained in a statement.

Financial terms of the agreement were not released.

Filed under

Molecular Diagnostics

Clinical Sequencing

Biomarker Discovery & Validation

Research Funding

codevelopment agreement

research alliance

sequencing-based diagnostics

biomarker panel

Foundation Medicine

J&J

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.